Aimmune Therapeutics, the company behind the AR101 oral immunotherapy (OIT) treatment for peanut allergy, announced on Dec. 20, 2018 that… Read more »
Meet the teenager impacting research as an intern and study participant.
The drug, based on the compound larazotide acetate, has received FDA “fast track” designation.
In a long-term follow-up study, oral immunotherapy (OIT) patients who were treated for up to five food allergies were able to maintain a high level of desensitization to their allergens, even those taking very low “doses” of their allergens.
Review found slightly increased risk of suffering from heart attacks, mini-strokes with the injectable drug.